Leatherman M E, Ekstrom R D, Corrigan M, Carson S W, Mason G, Golden R N
Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill 27599-7160.
Psychopharmacol Bull. 1993;29(2):149-54.
We employed a neuroendocrine challenge paradigm to study the effects of antidepressant treatment on serotonergic systems in depressed patients. We compared the maximum prolactin response to intravenous clomipramine (CMI) in depressed patients who responded to antidepressant treatment to that of nonresponders. Pretreatment baseline prolactin concentrations and pretreatment prolactin responses to clomipramine challenge were not different in responders compared to non-responders. However, following antidepressant treatment, the 6 responders demonstrated a significant change in their clomipramine challenge test results, as indicated by an increase in prolactin responses. In contrast, the 7 nonresponders did not demonstrate a change in their prolactin response to clomipramine challenge following treatment. These data support the hypothesis that serotonergic system dysfunction, as manifested by blunted prolactin response to clomipramine challenge, tends to normalize after successful treatment for depression, and that abnormal serotonergic function may be a state-dependent characteristic.
我们采用神经内分泌激发范式来研究抗抑郁治疗对抑郁症患者血清素能系统的影响。我们比较了对抗抑郁治疗有反应的抑郁症患者与无反应者对静脉注射氯米帕明（CMI）的最大催乳素反应。与无反应者相比，有反应者的治疗前基线催乳素浓度和治疗前对氯米帕明激发的催乳素反应并无差异。然而，在抗抑郁治疗后，6名有反应者的氯米帕明激发试验结果出现了显著变化，表现为催乳素反应增加。相比之下，7名无反应者在治疗后对氯米帕明激发的催乳素反应并未出现变化。这些数据支持了以下假设：以对氯米帕明激发的催乳素反应迟钝为表现的血清素能系统功能障碍，在成功治疗抑郁症后往往会恢复正常，并且血清素能功能异常可能是一种状态依赖性特征。
